Aptevo Therapeutics entered into warrant inducement agreements resulting in the cash exercise of existing warrants for 2,777,778 shares at a reduced price of $1.08 per share. The company received $3.0 million in gross proceeds and issued new 'reload' warrants for up to 13,888,890 additional shares to the participating holders. Proceeds will be used for working capital and general corporate purposes.
Aptevo Therapeutics presented new preclinical data for its multispecific platform candidates APVO451, APVO452, and APVO711 at the SITC 2026 Annual Meeting. The data demonstrated the molecules' ability to activate immune pathways and promote tumor-cell killing even under immunosuppressive conditions typical of solid tumors. These findings support the continued development of the company's portfolio of CD40-stimulating cancer immunotherapies.
Aptevo Therapeutics announced a clinical milestone for mipletamig in frontline AML, achieving a substantial reduction in infusion-related reactions (IRRs) through a refined priming-dose regimen. This optimization, identified through FDA discussions, improves patient tolerability in the ongoing RAINIER study as the company prepares for Phase 2 development.
“We have made substantial progress in improving mipletamig’s tolerability for patients with frontline AML. Mipletamig has demonstrated a differentiated safety and tolerability profile, and successive refinements to the priming-dose regimen have substantially reduced the occurrence of infusion-related reactions. Reducing these reactions matters to patients: it has the potential to make treatment easier to tolerate and limit complications that can disrupt care. These findings are an important part of our preparations for the next stage of clinical development.”
Dirk Huebner, M.D., Chief Medical Officer of Aptevo Therapeutics
Aptevo Therapeutics filed a prospectus supplement to its existing at-the-market (ATM) offering agreement with Roth Capital Partners, allowing for the potential sale of up to $2.3 million in common stock. The company disclosed that it has already raised $11.8 million in gross proceeds through the sale of 303,157 shares under the program to date.
Aptevo Therapeutics reported clinical data from its Phase 1b RAINIER trial showing that 21% of frontline AML patients treated with mipletamig combination therapy advanced to potentially curative stem cell transplants. This transplant rate compares favorably to historical standard-of-care results (0.7% in the VIALE-A trial) for patients initially deemed unfit for intensive chemotherapy. The company expects to conclude dose optimization by year-end and initiate a Phase 2 trial in the first half of 2027.